Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units
Year: 2025
Type: article
Study design: Observational Study
Abstract: ABSTRACT: Parvovirus B19 infection can lead to severe complications in patients with chronic hemolysis. The aim of this study was to describe severe parvovirus B19 infections in adult patients with sickle cell disease (SCD). In this multicenter, retrospective, observational cohort study, adult patients with SCD admitted to intensive care units (ICUs) between 2011 and 2024 with acute parvovirus B19 infection were included. Unsupervised analysis was performed including clinical and biological characteristics to identify clusters of patients with different outcomes. Clinical phenotypes were defined based on patient clustering. Parvovirus B19 genomes from ICU (n = 15) and non-ICU control patients (n = 15) admitted to the hospital during the same period were sequenced and compared. Sixty-one patients (52% female; median age, 29 years [interquartile range, 24-38]) from 8 ICUs in France were included. Three clusters of patients were identified. From these clusters, 3 groups of patients with distinct clinical phenotype were identified: erythroblastopenia (n = 26), bone marrow necrosis (BMN) and fat cerebral embolism syndrome (CFE; n = 17), and other vaso-occlusive manifestations (n = 18). Length of stay in the ICU and hospital was longer in patients with BMN/CFE. There was no difference in parvovirus B19 genotype or NS1 or VP1/2 amino acid diversity between the groups. Similar results were observed between patients who were admitted to the ICU and those who were not. ICU patients with SCD and acute parvovirus B19 infection presented 3 clinical phenotypes associated with different initial severity and outcome but with similar parvovirus B19 clades and amino acid diversity.
Source: Blood Advances
Authors: Ségolène Gendreau, Louis-Marie Coupry, Pierre Cappy, Alexandra Beurton, Nicolas Verger, Anoosha Habibi, Maïté Agbakou, Sylvain Le Jeune, Laurent Argaud, Serge Barmo, Gauthier Blonz, Pierre Cougoul, Stéphanie Houcke, Antoine Lafarge, Arnaud Ly, Andréa Pastissier, Armand Mekontso Dessap, Slim Fourati, Nicolas de Prost
Institutions: Université Paris-Est Créteil, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, Institut Mondor de Recherche Biomédicale, Hôpital Tenon, Centre Hospitalier Universitaire de Nantes, Hôpital Avicenne, Hospices Civils de Lyon, Hôpital Edouard Herriot, Hôpital Antoine-Béclère, Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Andrée Rosemon, Hôpital Saint-Louis, Inserm
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
Funders: AstraZeneca, GlaxoSmithKline, Moderna
OpenAlex ID: W4411370712
